ICAM1 and neoplasm: In vivo imaging results showed that, in comparison with non-targeted IgG-Cy5.5, ICAM1-Cy5.5 and ICAM1-MMAE-Cy5.5 had significantly higher accumulation at CCA tumor sites (Fig. 4b).